Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on Sagimet Biosciences (NASDAQ: SGMT) and has raised the price target from $25 to $26.